Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...
Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only ...
Please provide your email address to receive an email when new articles are posted on . “Previous studies have shown that the risk of cardiac events is significantly increased in [long QT syndrome] ...
Less than 1 percent of the population has been diagnosed with Long QT syndrome – a rare heart condition that can cause chaotic, sometimes fatal, heart rhythms. Now, Virginia Tech researchers at the ...
A machine learning model was more effective at detecting congenital long QT syndrome on resting ECGs than manual measurement of QT intervals by arrhythmia experts, in a new study. Researchers ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
MONTREAL, Jan. 13, 2026 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results